Publications by authors named "R Jaksa"
Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. We analyzed 124 primary ovarian mucinous tumors originally diagnosed as mucinous borderline tumors (MBTs) or mucinous carcinomas (MCs), with an emphasis on interobserver diagnostic agreement and the potential for diagnostic support by molecular profiling using a next-generation sequencing targeted panel of 727 DNA and 147 RNA genes. Fourteen experienced pathologists independently assigned a diagnosis from preset options, based on a review of a single digitized slide from each tumor.
View Article and Find Full Text PDFArticle Synopsis
- Clear cell (hemangioblastoma-like) stromal tumor of the lung (CCSTL) is a rare type of lung tumor, and recent findings link it to the YAP1-TFE3 gene fusion.
- A case study featured a 57-year-old male with a 45 mm lung nodule, showing specific microscopic and immunohistochemical characteristics.
- The study's results reinforce the idea that the YAP1-TFE3 fusion is a typical feature of CCSTL, potentially helping in its classification and understanding.
We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed 15 different PDX models from various NHL types, confirming that PDXs retained the genetic diversity of the original tumors through whole exome sequencing (WES).
- * However, the tumor microenvironment (TME) in PDXs showed notable differences, including altered cell morphology, reduced immune cell presence, and lower blood vessel density, suggesting that while genetic profiles are maintained, the PDXs do not fully replicate the original cancer environment.
Article Synopsis
- MCL1 protein is commonly overexpressed in various cancers, including B-cell non-Hodgkin lymphomas (B-NHL), and its specific inhibitor, S63845, was studied for its effectiveness in treating these cancers.
- The research found that the expression levels of BCL2 protein significantly affect how lymphoma cells respond to S63845, with BCL2-positive cells showing resistance and BCL2-negative cells being more susceptible to treatment.
- Combining S63845 with another drug, venetoclax, proved to be particularly effective for overcoming resistance in BCL2-positive lymphoma models, highlighting the importance of both MCL1 and BCL2 levels in treatment outcomes.